How Does Toxicity Negatively Impact Efficacy?
The Impact Increases Post Second Line
Many patients with mRCC require dose reductions or interruptions to tolerate TKI treatment, including in the relapsed or refractory setting, leading to underutilization or no treatment3-7
Across TKI pivotal trials, dose reductions, dose interruptions, and discontinuations due to AEs are high—
with dose interruptions affecting up to 4 out of 5 patients8,11
AEs=adverse events; mRCC=metastatic renal cell carcinoma;
TKI=tyrosine kinase inhibitor.